Member of the Association of American Physicians
Robert H. Vonderheide mostly deals with Immunology, Immune system, Immunotherapy, CD8 and Cancer research. His Immunology research is multidisciplinary, incorporating elements of Cytotoxic T cell and Cancer. His Immune system study combines topics in areas such as Phenotype, Myeloid and Monoclonal.
His studies deal with areas such as Carcinogenesis, CD40 and Immunosurveillance as well as Immunotherapy. His studies in CD8 integrate themes in fields like Hepatitis C, Virus, Telomerase, Telomerase reverse transcriptase and Major histocompatibility complex. His Tumor microenvironment study in the realm of Cancer research connects with subjects such as Epigenomics.
The scientist’s investigation covers issues in Immunology, Cancer research, Immune system, Immunotherapy and Cancer. His research on Immunology frequently connects to adjacent areas such as Cytotoxic T cell. His Cancer research research includes themes of Immune checkpoint, Gemcitabine, Pancreatic cancer and CD40.
The various areas that Robert H. Vonderheide examines in his Immune system study include Cell, Blockade, Antibody and Adenocarcinoma. In his research, CTL* is intimately related to Telomerase reverse transcriptase, which falls under the overarching field of Immunotherapy. The concepts of his Cancer study are interwoven with issues in Melanoma and Pathology.
Robert H. Vonderheide focuses on Cancer research, Immune system, Cancer, Immunotherapy and T cell. His research integrates issues of Immune checkpoint, CD8, Pancreatic cancer and CD40 in his study of Cancer research. His Immune system study improves the overall literature in Immunology.
His study in Immunology is interdisciplinary in nature, drawing from both Missense mutation and Myeloid-derived Suppressor Cell. Robert H. Vonderheide combines subjects such as Mutation and MEDLINE with his study of Cancer. His Immunotherapy research incorporates themes from Tumor necrosis factor alpha and Adenocarcinoma.
His scientific interests lie mostly in Cancer research, Immunotherapy, Immunology, T cell and Immune system. His Cancer research study incorporates themes from Cancer, Breast cancer, Tumor progression and KRAS. The study incorporates disciplines such as Cytotoxic T cell, CD40 and Pancreatic cancer in addition to Immunotherapy.
His work in Immunology is not limited to one particular discipline; it also encompasses Myeloid-derived Suppressor Cell. His T cell study integrates concerns from other disciplines, such as Tumor necrosis factor alpha, Cell culture and Blockade. His Immune system study combines topics from a wide range of disciplines, such as Phenotype, Hematopoietic stem cell transplantation and Adenocarcinoma.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
EMT and Dissemination Precede Pancreatic Tumor Formation
Andrew D. Rhim;Emily T. Mirek;Nicole M. Aiello;Anirban Maitra.
CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
Gregory L. Beatty;Elena G. Chiorean;Matthew P. Fishman;Babak Saboury.
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Christina Twyman-Saint Victor;Andrew J. Rech;Amit Maity;Ramesh Rengan;Ramesh Rengan.
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
Vincenzo Bronte;Sven Brandau;Shu Hsia Chen;Mario P. Colombo.
Nature Communications (2016)
Dynamics of the Immune Reaction to Pancreatic Cancer from Inception to Invasion
Carolyn E. Clark;Sunil R. Hingorani;Rosemarie Mick;Chelsea Combs.
Cancer Research (2007)
Tumor-Derived Granulocyte-Macrophage Colony-Stimulating Factor Regulates Myeloid Inflammation and T Cell Immunity in Pancreatic Cancer
Lauren J. Bayne;Gregory L. Beatty;Nirag Jhala;Carolyn E. Clark.
Cancer Cell (2012)
The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes.
Robert H Vonderheide;William C Hahn;William C Hahn;Joachim L Schultze;Lee M Nadler.
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response
Alexander C. Huang;Michael A. Postow;Michael A. Postow;Robert J. Orlowski;Rosemarie Mick.
Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade.
Joseph L. Benci;Bihui Xu;Yu Qiu;Tony J. Wu.
Clinical Activity and Immune Modulation in Cancer Patients Treated With CP-870,893, a Novel CD40 Agonist Monoclonal Antibody
Robert H. Vonderheide;Keith T. Flaherty;Magi Khalil;Molly S. Stumacher.
Journal of Clinical Oncology (2007)
Profile was last updated on December 6th, 2021.
Research.com Ranking is based on data retrieved from the Microsoft Academic Graph (MAG).
The ranking d-index is inferred from publications deemed to belong to the considered discipline.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: